Nasdaq: DNLI
Denali Therapeutics insiders
The officers, directors and 10% owners of Denali Therapeutics Inc. who hold the most stock, valued at the live DNLI price.
$18.20
DNLI today −$200K (−1.09%)
Market closed. Prices as of Nov 19, 4:04 PM ET
- Ranked insiders
- 8
- Their DNLI stock
- $127M
- Market value
- $2.92B
- Held by ranked insiders
- 4.36%
Insiders by value of DNLI holdings
SEC ownership page| # | Insider | Role | Shares | Value | Of company | Overall rank |
|---|---|---|---|---|---|---|
| 1 | Ryan J. Watts | President and CEO | 2,417,217 | $44.0M | 1.51% | 2788th |
| 2 | Marc Tessier-Lavigne | Director | 1,965,424 | $35.8M | 1.23% | 3118th |
| 3 | Steve Krognes | Director | 819,999 | $14.9M | 0.51% | 6089th |
| 4 | Alexander O. Schuth | COFO and Secretary | 819,310 | $14.9M | 0.51% | 6473rd |
| 5 | Carole Ho | Chief Medical Officer | 424,804 | $7.7M | 0.27% | 9813th |
| 6 | Jay T. Flatley | Director | 358,941 | $6.5M | 0.22% | 9871st |
| 7 | Vicki L. Sato | Director | 107,976 | $2.0M | <0.1% | 7843rd |
| 8 | David P. Schenkein | Director | 79,129 | $1.4M | <0.1% | 6200th |
Only insiders worth at least $5 million in listed stock are ranked. Holdings come from each insider's latest Form 3, 4 or 5 for Denali Therapeutics; see each profile for the filing.